TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Senzime AB ( (SE:SEZI) ) just unveiled an announcement.
Senzime AB has welcomed new European pediatric guidelines recommending EMG-based neuromuscular monitoring during anesthesia, a technology utilized by their TetraGraph system. This development is significant for pediatric patient safety and presents new market opportunities for Senzime, as their system is specifically designed for pediatric use and is already in use at leading hospitals.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is renowned for its accuracy in monitoring neuromuscular transmission during surgery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 573,136
Technical Sentiment Signal: Sell
Current Market Cap: SEK979.4M
For a thorough assessment of SEZI stock, go to TipRanks’ Stock Analysis page.